scholarly journals Fetal and Maternal Outcomes of Gestational Thyrotoxicosis: Single Center Experience, Retrospective Cohort

2020 ◽  
Vol 53 (1) ◽  
pp. 1-5
Author(s):  
Nazlı GÜLSOY KİRNAP ◽  
Sanem KAYHAN
Keyword(s):  
Retrospective Cohort ◽  
Maternal Outcomes ◽  
Single Center ◽  
Single Center Experience

scholarly journals Epidemiology and Management of Children with Hypertensive Crisis: A Single-Center Experience

2019 ◽  
Vol 09 (01) ◽  
pp. 045-050
Author(s):  
Alicia May Lim ◽  
Siew Le Chong ◽  
Yong Hong Ng ◽  
Yoke Hwee Chan ◽  
Jan Hau Lee
Keyword(s):  
Cohort Study ◽  
Retrospective Cohort Study ◽  
Retrospective Cohort ◽  
Hypertensive Crisis ◽  
Hypertensive Emergency ◽  
Renal Pathology ◽  
Pediatric Hospital ◽  
Single Center ◽  
Single Center Experience ◽  
Effective Treatments

AbstractMost children who present with hypertensive crisis have a secondary cause for hypertension. This study describes the epidemiology and management of children with hypertensive crisis. A retrospective cohort study was done in a tertiary pediatric hospital from 2009 to 2015. Thirty-seven patients were treated for hypertensive crisis. Twelve (32.4%) patients were treated for hypertensive emergency. The majority of our patients (33 [89.1%]) had a secondary cause of hypertension. The most common identifiable cause of hypertension was a renal pathology (18/37 [48.6%]). Oral nifedipine (23 [62.1%]) was the most frequently used antihypertensive, followed by intravenous labetalol (8 [21.6%]). There were no mortalities or morbidities. Hypertensive crisis in children is likely secondary in nature. Oral nifedipine and intravenous labetalol are both effective treatments.

scholarly journals History of Adverse Pregnancy on Subsequent Maternal-Fetal Outcomes in Patients with Immunoglobulin A Nephropathy: A Retrospective Cohort Study from a Chinese Single Center

2021 ◽  
pp. 1-8
Author(s):  
Xingji Lian ◽  
Li Fan ◽  
Xin Ning ◽  
Cong Wang ◽  
Yi Lin ◽  
...  
Keyword(s):  
Cohort Study ◽  
Retrospective Cohort ◽  
Immunoglobulin A ◽  
Maternal Outcomes ◽  
Single Center ◽  
Immunoglobulin A Nephropathy ◽  
Fetal Outcomes ◽  
Increased Risk ◽  
History Of ◽  
Adverse Pregnancy

<b><i>Background:</i></b> Gestation complications have a recurrence risk and could predispose to each other in the next pregnancy. We aimed to evaluate the relationship between a history of adverse pregnancy and maternal-fetal outcomes in subsequent pregnancy in patients with Immunoglobulin A nephropathy (IgAN). <b><i>Methods:</i></b> A retrospective cohort study from a Chinese single center was conducted. Pregnant women with biopsy-proven primary IgAN and aged ≥18 years were enrolled and divided into the 2 groups by a history of adverse pregnancy. The primary outcome was adverse pregnancy outcome, which included maternal-fetal outcomes. Logistical regression model was used to evaluate the association of a history of adverse pregnancy with subsequent adverse maternal and fetal outcomes. <b><i>Results:</i></b> Ninety-one women with 100 pregnancies were included, of which 54 (54%) pregnancies had a history of adverse pregnancy. IgAN patients with adverse pregnancy history had more composite maternal outcomes (70.4% vs. 45.7%, <i>p</i> = 0.012), while there was no difference in the composite adverse fetal outcomes between the 2 groups (55.6% vs. 45.7%). IgAN patients with a history of adverse pregnancy were associated with an increased risk of subsequent adverse maternal outcomes (adjusted odds ratio [OR], 2.64; 95% CI, 1.07–6.47). Similar results were shown in those with baseline serum albumin &#x3c;3.5 g/dL, 24 h proteinuria ≥1 g/day, and a history of hypertension. There was no association between a history of adverse pregnancy and subsequent adverse fetal outcomes in IgAN patients (adjusted OR, 1.56; 95% CI, 0.63–3.87). <b><i>Conclusion:</i></b> A history of adverse pregnancy was associated with an increased risk of subsequent adverse maternal outcomes, but not for adverse fetal outcomes in IgAN patients.

scholarly journals 1742. Kinetics of CMV Viremia with Letermovir Prophylaxis in the First 100 Days post Hematopoietic Cell Transplantation (HCT): A Single-center Experience

2019 ◽  
Vol 6 (Supplement_2) ◽  
pp. S638-S638
Author(s):  
Phaedon D Zavras ◽  
Anat Stern ◽  
Yiqi Su ◽  
Jiaqi Fang ◽  
Sergio Giralt ◽  
...  
Keyword(s):  
Retrospective Cohort ◽  
Hematopoietic Cell Transplantation ◽  
Preemptive Therapy ◽  
Single Center ◽  
Cmv Infection ◽  
Single Center Experience ◽  
Clinically Significant ◽  
Kinetics Of ◽  
Cmv Reactivation ◽  
Historical Controls

Abstract Background Letermovir (LTV) is approved for the prevention of CMV infection in CMV seropositive (R+) HCT recipients. Low rates of CMV breakthrough viremia have been reported with LTV prophylaxis. We studied the kinetics of CMV reactivation up to day (D) +100 in patients (patients) receiving LTV prophylaxis and compared them to historical controls not receiving LTV. Methods Retrospective cohort study of CMV R+ recipients of peripheral blood or marrow allografts at MSKCC during 2017–2018. Routine LTV prophylaxis was implemented in MSKCC in December 2017. Patients were categorized based on LTV prophylaxis to LTV group (LTV prophylaxis) and no LTV group [managed with preemptive therapy (PET)]. Routine CMV monitoring was performed weekly by a qPCR assay in plasma from D +14 through D +100. CMV viremia was defined as any detectable CMV viral load (VL). Clinically significant CMV viremia (csCMV) was defined as any CMV VL treated preemptively. CMV end-organ disease (EOD) was assessed by standard criteria. LTV resistance was tested at Viracor-Eurofins Laboratories after May 2018. Results Of 193 R+ HCT, 98 (50.8%) were in the LTV and 95 (49.2%) in the no LTV group. CMV viremia occurred in 43 (43.9%) patients in LTV and 63 (66.3%) in no LTV (Figure 1). CMV viremia occurred earlier in LTV compared with no LTV (median, 19 vs. 26 days post HCT, respectively, P = 0.009). The duration of CMV viremia was shorter in LTV compared with no LTV (median 16 days vs. 35 days, respectively; P < 0.0001). The peak CMV VL was lower in LTV compared with no LTV (median, 137 IU/mL vs. 578 IU/mL, respectively); P < 0.0001. Rates of csCMV viremia were significantly lower in LTV compared with no LTV (5.1% vs. 54%, respectively); P < 0.0001 (Figure 2). LTV group received a total of 134 PET-days and no LTV group received 2,160 PET-days by D +100. No patient in LTV developed CMV EOD, while two patients in no LTV developed CMV duodenitis. LTV resistance was documented in 2 patients (2% of the LTV group). Overall survival by D +100 was similar between LTV and no LTV groups. Conclusion Implementation of LTV prophylaxis significantly reduced rates of csCMV infection and resulted in 93.8% reduction in total PET days. Among patients with csCMV viremia, LTV group had a shorter duration of viremia and lower peak CMV VL compared with no LTV. Disclosures All authors: No reported disclosures.

scholarly journals Maternal outcomes of pregnancy in women with mechanical heart valves prostheses — a single-center experience

2021 ◽  
Vol 79 (11) ◽  
pp. 1262-1264
Author(s):  
Agnieszka Bartczak-Rutkowska ◽  
Olga Trojnarska ◽  
Aleksandra Ciepłucha ◽  
Wiesław Markwitz ◽  
Maciej Lesiak
Keyword(s):  
Heart Valves ◽  
Mechanical Heart Valves ◽  
Maternal Outcomes ◽  
Single Center ◽  
Single Center Experience

A retrospective study of sedation and analgesic requirements of pediatric patients on extracorporeal membrane oxygenation (ECMO) from a single-center experience

Perfusion ◽  
2016 ◽  
Vol 32 (3) ◽  
pp. 183-191 ◽  
Author(s):  
Pilar Anton-Martin ◽  
Vinai Modem ◽  
Donna Taylor ◽  
Donald Potter ◽  
Cindy Darnell-Bowens
Keyword(s):  
Retrospective Cohort ◽  
Pediatric Patients ◽  
Pediatric Intensive Care ◽  
Muscle Relaxants ◽  
Second Line ◽  
Single Center ◽  
First Line ◽  
Factors Associated ◽  
Single Center Experience ◽  
Younger Age

Introduction: The purpose of this study is to describe the sedative and analgesic requirements identifying factors associated with medication escalation in neonates and children supported on ECMO. Method: Observational retrospective cohort study in a tertiary pediatric intensive care unit from June 2009 to June 2013. Results: One hundred and sixty patients were included in the study. Fentanyl and midazolam were the first line agents used while on ECMO. Higher opiate requirements were associated with younger age (p=0.01), thoracic cannulation (p=0.002), the use of dexmedetomidine (p=0.007) and prolonged use of muscle relaxants (p=0.03). Higher benzodiazepine requirements were associated with younger age (p=0.01), respiratory failure (p=0.02) and the use of second line agents (p=0.002). One third of the patients required second line agents as adjuvants for comfort without a decrease in opiate and/or benzodiazepine requirements. Conclusions: Providing comfort to subpopulations of pediatric ECMO patients seems to be more challenging. The use of second line agents did not improve comfort in our cohort. Prospective studies are required to optimize analgesia and sedation management in children on ECMO.

Sign in / Sign up

Export Citation Format

Share Document